Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Plasma cell 1Other 1

Conditions

Obesity 95Overweight 36Neoplasms 33Breast Neoplasms 24Sexual Dysfunction, Physiological 19Dyspnea 16Weight Loss 13Motor Activity 13Endometrial Neoplasms 11Polycystic Ovary Syndrome 10Mucositis 8Diabetes Mellitus, Type 2 8Diabetes Mellitus 8Obesity-Related Malignant Neoplasm 7Hypertension 7Depression 7Anxiety Disorders 7Pediatric Obesity 6Lung Neoplasms 6Constipation 6Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Sexual Dysfunctions, Psychological 5Pulmonary Disease, Chronic Obstructive 5Obesity, Morbid 5Leukemia 5Endometrial Hyperplasia 5Disease 5Sedentary Behavior 4Prostatic Neoplasms 4

Interventions

isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Hemorrhage × Other × 1 year × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡